
|Videos|June 13, 2022
Dr. Lotan on the iodine-based contrast media shortage
Author(s)Urology Times staff
“For patients who are several years out from treatment for bladder cancer or kidney cancer, I don't think [the shortage is] going to have a clinical impact. For more acute settings, I have tried to rely a little bit more on MR urograms and ultrasound,” says Yair Lotan, MD.
Advertisement
In this interview, Yair Lotan, MD, is a professor of urology, chief of Urologic Oncology, the Jane and John Justin Distinguished Chair in Urology, in honor of Claus G. Roehrborn, MD, and vice chair of clinical affairs at the University of Texas Southwestern Medical Center in Dallas.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Real-world data support PSA below 0.2 ng/mL as key response threshold in mCSPC
2
The UroOnc Minute: Navigating BCG Maintenance Therapy in NMIBC, With Mark D. Tyson, II, MD, MPH
3
Published data show rPFS benefit with lutetium Lu 177 vipivotide tetraxetan in mHSPC
4
The AUA Clinically Localized Prostate Cancer guideline: FAQs for urologists
5








